Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTH | P32929 | 4/20 | 0.53 |
| ▸ | NFE2L2 | Q16236 | 15/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22579089 | 1.00 | CTH (0.53) | CTHNFE2L2LMNARAB9ASMN1; SMN2 | |
| SCHEMBL20913089 | 0.80 | CTH (0.53) | CTHNFE2L2LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2236093 | 0.80 | CTH (0.53) | CTHNFE2L2LMNARAB9ASMN1; SMN2 | |
| SCHEMBL30139582 | 0.80 | CTH (0.53) | CTHNFE2L2LMNARAB9ASMN1; SMN2 | |
| SCHEMBL2236095 | 0.80 | CTH (0.53) | CTHNFE2L2LMNARAB9ASMN1; SMN2 | |
| SCHEMBL23420036 | 0.78 | CTH (0.51) | CTHLMNARAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL19003421 | 0.78 | CTH (0.51) | CTHLMNARAB9ASMN1; SMN2L3MBTL1 | |
| SCHEMBL19814690 | 0.77 | — | — | |
| SCHEMBL28350245 | 0.77 | — | — | |
| SCHEMBL20689252 | 0.76 | SMN1; SMN2 (0.37) | CTHLMNARAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) | 2023-05-04 | — | — | US | disclosed |
| US-20210164005-A1 | METHODS FOR INDUCING BIOORTHOGONAL REACTIVITY | UNIVERSITY OF DELAWARE (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2020035052-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-02-20 | — | — | WO | disclosed |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | AVISTA PHARMA SOLUTIONS, INC. | 2017-07-20 | — | — | US | disclosed |
| US-9643963-B2 | Antiparasitic compounds | AVISTA PHARMA SOLUTIONS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139111-A1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | RIPK1, RIPK4, RIPK3 | CTH 4038/4885NFE2L2 3848/4885LMNA 1598/4885 |
| US-20170202849-A1 | ANTIPARASITIC COMPOUNDS | TPP2, TPP1, SERPINB1 | CTH 936/4885NFE2L2 3899/4885LMNA 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.